Stockscreener 앱 받기
0.759
3.97%
0.029
시간 외 거래:
.76
0.001
+0.13%
Acurx Pharmaceuticals Inc 주식(ACXP)의 최신 뉴스
Geode Capital Management LLC Increases Stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) - Defense World
A History of Outperforming Analyst Forecasts and Beating the Odds: Acurx Pharmaceuticals Inc (ACXP) - SETE News
HC Wainwright Reaffirms Buy Rating for Acurx Pharmaceuticals (NASDAQ:ACXP) - Defense World
Acurx Pharmaceuticals (NASDAQ: ACXP) Announces $2.5 Million Registered Direct Offering - Defense World
Acurx pharmaceuticals director Carl Sailer acquires shares worth $25,000 - Investing.com
Acurx pharmaceuticals director Joseph Scodari acquires $25,000 in stock - Investing.com
Acurx pharmaceuticals director Carl Sailer acquires shares worth $25,000 By Investing.com - Investing.com UK
Acurx Pharmaceuticals director buys $9,999 in common stock - Investing.com
Acurx Pharmaceuticals director Robert DeLucca buys $49,999 in stock By Investing.com - Investing.com South Africa
ACXP stock touches 52-week low at $0.72 amid market challenges - Investing.com Canada
Acurx Pharmaceuticals Secures $2.5M Financing Through Direct Offering and Warrant Placement - StockTitan
Form 424B5 Acurx Pharmaceuticals, - StreetInsider.com
SEC Form 424B5 filed by Acurx Pharmaceuticals Inc. - Quantisnow
Acurx to sell 2.46M shares at $1.015 in registered direct offering - MSN
Acurx Pharmaceuticals announces $2.5 million registered direct offering - MSN
Acurx gains EMA support for ibezapolstat Phase 3 trial By Investing.com - Investing.com Nigeria
Acurx gains EMA support for ibezapolstat Phase 3 trial - Investing.com
Acurx's Ibezapolstat Secures EMA Backing for Phase 3 C. Difficile Treatment Program - StockTitan
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year? - Yahoo Finance
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Increase in Short Interest - Defense World
Acurx Pharmaceuticals to Present Latest Antibiotic Developments at 2025 Microcap Conference - StockTitan
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025January 30, 2025 - Eagle-Tribune
Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024 - Kilgore News Herald
Acurx prepares for Phase 3 trials in C. difficile treatment By Investing.com - Investing.com Canada
Acurx prepares for Phase 3 trials in C. difficile treatment - Investing.com India
Acurx's Breakthrough CDI Antibiotic Advances Toward Global Phase 3 Trial Following FDA Green Light - StockTitan
ACXP stock touches 52-week low at $0.79 amid market challenges - Investing.com UK
Here's Why Acurx Pharmaceuticals (ACXP) Is a Great 'Buy the Bottom' Stock Now - MSN
ACXP stock touches 52-week low at $1.01 amid market challenges - Investing.com Canada
Novavax and Assembly lead infectious disease gainers in 2024 - BioWorld Online
MicroStrategy Now Has Copycats Buying Bitcoin as Prices Near $100,000 - Barron's
Nasdaq-Listed Acurx Invests $1M in Bitcoin—What’s Behind the Move? - Watcher Guru
Acurx Pharmaceuticals Allocates $1 Million to Bitcoin as Reserve Asset, Shares Slide 26% - Binance
Acurx Pharmaceuticals Shares Slide 17% After Disclosing Bitcoin Investment - MarketWatch
Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbook - MSN
ACXP stock touches 52-week low at $1.5 amid market challenges - Investing.com UK
Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset - Il Giornale d'Italia
Acurx Pharmaceuticals adopts Bitcoin as a reserve asset - TU News
Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset | DigitalMore.co - Digital More
Acurx Pharmaceuticals allocates $1M for Bitcoin reserve - Investing.com
Acurx Pharmaceuticals allocates $1M for Bitcoin reserve By Investing.com - Investing.com UK
ACXPAcurx Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Acurx Pharma Advances CDI Drug to Phase 3 Trials After Promising Clinical Data | ACXP Stock News - StockTitan
HC Wainwright Has Bullish Estimate for ACXP FY2024 Earnings - Defense World
Acurx Pharmaceuticals Reports Q3 2024 Financial Results and Business Update - Defense World
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Decline in Short Interest - Defense World
Acurx Pharmaceuticals’ (ACXP) Buy Rating Reiterated at HC Wainwright - Defense World
5.49%
0.79%
자본화:
|
볼륨(24시간):